Antibiotic Side Effect Clinical Trial
Official title:
Short Against Long Antibiotic Therapy for Infected Orthopedic Sites
The investigators will perform two concomitant RCTs, depending on the presence of infected osteosynthesis material at enrolment: - SALATIO 1. Infected implant not removed (or new material inserted): Randomization 6 vs. 12 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy. - SALATIO 2. Infected implant without residual material (definitive removal or within the interval of a two-stage exchange): Randomization 3 vs. 6 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy.
The optimal duration of postoperative, systemic antibiotic therapy for implant-related orthopedic infections, with or without implant removal, is unknown. Retrospective studies suggest that a maximum duration of 6 weeks is not inferior to longer administrations; even if the infected implants are kept in place or during a one-stage exchange. Prospective-randomized trials (RCT) suggest that even shorter durations, such 3 or 4 weeks, are possible, when the implant is removed. Likewise, in prospective studies, 6 or 8 weeks of systemic antibiotics are not inferior to the current 12 weeks during DAIR (debridement, antibiotic and implant retention), or during the one-stage exchange; except for one single RCT suggesting a better outcome for 12 weeks in the substrata of arthroplasty infections undergoing the DAIR procedure. However, these RCTs concern selected branches of orthopedic surgery; especially prosthetic joint infections. The investigators intend to expand these evaluations to all fields of orthopedic and hand surgery. The only exceptions would be spine surgery, for which a multicenter, separate RCT is already under way (SASI-trials). The second exception would be the treatment of implant-free diabetic foot infections, for which two RCTs are underway. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04081792 -
Optimal Antibiotics for Operated Diabetic Foot Infections
|
N/A | |
Recruiting |
NCT05950984 -
Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK)
|
||
Completed |
NCT03199911 -
Topical Antibiotic Prophylaxis for Eyelids
|
Phase 4 | |
Completed |
NCT05355571 -
The Impact of Probiotic Supplementation on Antibiotic Induced Changes in Gastrointestinal Function and/or Faecal Microbiota Composition
|
N/A | |
Recruiting |
NCT05699174 -
PO vs IV Antibiotics for the Treatment of Infected Nonunion of Fractures After Fixation
|
Phase 3 | |
Completed |
NCT03087890 -
Impact of Cotrimoxazole Use in Immunocompetent HIV Patients on Carriage of Antimicrobial Resistant Bacteria
|
Phase 4 | |
Completed |
NCT01254097 -
Probiotics in Primary Care
|
N/A | |
Recruiting |
NCT06018792 -
Molecular Culture for the Diagnosis of Pediatric Sepsis
|
||
Completed |
NCT06030713 -
Timing of Maternal Antibiotic Prophylaxis During a Cesarean Section and the Early Infant Gut Microbiome
|
N/A | |
Active, not recruiting |
NCT05027893 -
Complications After Lower Third Molar Surgery
|
N/A | |
Not yet recruiting |
NCT03935828 -
Effect of Topical Sinonasal Antibiotics
|
Phase 2 | |
Not yet recruiting |
NCT06383637 -
Antibiotic Use and Resistance KAP Among Dental Interns
|
||
Enrolling by invitation |
NCT04707092 -
Use of Preoperative and Postoperative Antimicrobial Treatment
|
Phase 4 | |
Not yet recruiting |
NCT06395454 -
Usage of Procalcitonin to Reduce Antibiotics Duration in VAP in Neurosurgical ICU
|
N/A | |
Recruiting |
NCT03932708 -
Improving Antibiotic Use in Urgent Care Facilities
|
N/A | |
Recruiting |
NCT04731025 -
Local Antibiotics for Breast Implants
|
Phase 3 | |
Completed |
NCT04403334 -
Postoperative Safety Outcomes of Intraoperative Intracameral Preservative-Free Moxifloxacin Versus Levofloxacin
|
Phase 4 | |
Completed |
NCT04127682 -
Antibiotic Prescription for Children With Acute Upper Respiratory Tract Infections in Assiut District
|
||
Completed |
NCT05742295 -
Prevention of Cefoperazone-induced Coagulopathy
|
Phase 4 | |
Not yet recruiting |
NCT06250413 -
Autoflor -Lyophilized Capsulated Autological FMT to Restore Gut Microbiome After Treatment With Antibiotics
|
N/A |